Skip to content

Study · Non-randomized trial · n = 121 · 2016

10 results

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.

Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, Li Volti G, Caprio M, Montalto G, Provenzano V, Genovese S, Ceriello A

Cardiovascular diabetology3 Dec 2016Cited by 114 (Europe PMC)

PMID27912784 (opens in a new tab)PMCIDPMC5135832 (opens in a new tab)DOI10.1186/s12933-016-0480-8 (opens in a new tab)PepBankPUB-27912784
Download PDFPubMedAsk about this study
Jump to 10 results

Summary

BackgroundLiraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes (T2DM), such as those on body weight, blood pressure, plasma lipids and inflammation markers. However, the effects of liraglutide on cardiovascular (CV) risk markers in subjects with the metabolic syndrome (MetS) are still largely unknown. We herein explored its effects on various cardio-metabolic risk markers of the MetS in subjects with T2DM.MethodsWe performed an 18-month prospective, real-world study. All subjects had T2DM and the MetS based on the AHA/NHLBI criteria. Subjects with a history of a major CV event were excluded. One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included. Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study. Fasting plasma samples for metabolic parameters were collected and carotid-intima media thickness (cIMT) was assessed by B-mode real-time ultrasound at baseline and every 6 months thereafter.ResultsThere was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up. Correlation analysis showed a significant association between changes in cIMT and triglycerides (r = 0.362; p < 0.0001). The MetS prevalence significantly reduced during the study, and the 26% of subjects no longer fulfilled the criteria for the MetS after 18 months.ConclusionsLiraglutide improves cardio-metabolic risk factors in subjects with the MetS in a real-world study. Trial Registration ClinicalTrials.gov: NCT01715428.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes and metabolic syndrome, waist circumference fell during 18 months of liraglutide added to metformin.

    In plain wordsIn adults with type 2 diabetes and metabolic syndrome, waist size fell over 18 months of liraglutide added to metformin.

    Peptide
    Liraglutide
    Outcome
    DecreaseWaist circumference
    Study

    n = 121

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.2 mg/day · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up.
    2 context sentences
    Summary · context
    One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included.
    Summary · context
    Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study.
  2. 02HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes and metabolic syndrome, body mass index fell during 18 months of liraglutide added to metformin.

    In plain wordsIn adults with type 2 diabetes and metabolic syndrome, body mass index fell over 18 months of liraglutide added to metformin.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index
    Study

    n = 121

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.2 mg/day · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up.
    2 context sentences
    Summary · context
    One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included.
    Summary · context
    Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study.
  3. 03HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes and metabolic syndrome, fasting glycemia fell during 18 months of liraglutide added to metformin.

    In plain wordsIn adults with type 2 diabetes and metabolic syndrome, fasting blood sugar fell over 18 months of liraglutide added to metformin.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting glycemia
    Study

    n = 121

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg/day · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up.
    2 context sentences
    Summary · context
    One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included.
    Summary · context
    Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study.
  4. 04HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes and metabolic syndrome, HbA1c fell during 18 months of liraglutide added to metformin.

    In plain wordsIn adults with type 2 diabetes and metabolic syndrome, HbA1c fell over 18 months of liraglutide added to metformin.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c
    Study

    n = 121

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg/day · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up.
    2 context sentences
    Summary · context
    One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included.
    Summary · context
    Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study.
  5. 05HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes and metabolic syndrome, total cholesterol fell during 18 months of liraglutide added to metformin.

    In plain wordsIn adults with type 2 diabetes and metabolic syndrome, total cholesterol fell over 18 months of liraglutide added to metformin.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal cholesterol
    Study

    n = 121

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    1.2 mg/day · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up.
    2 context sentences
    Summary · context
    One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included.
    Summary · context
    Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study.
  6. 06HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes and metabolic syndrome, LDL cholesterol fell during 18 months of liraglutide added to metformin.

    In plain wordsIn adults with type 2 diabetes and metabolic syndrome, LDL cholesterol fell over 18 months of liraglutide added to metformin.

    Peptide
    Liraglutide
    Outcome
    DecreaseLDL cholesterol
    Study

    n = 121

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    1.2 mg/day · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up.
    2 context sentences
    Summary · context
    One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included.
    Summary · context
    Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study.
  7. 07HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes and metabolic syndrome, triglycerides fell during 18 months of liraglutide added to metformin.

    In plain wordsIn adults with type 2 diabetes and metabolic syndrome, triglycerides fell over 18 months of liraglutide added to metformin.

    Peptide
    Liraglutide
    Outcome
    DecreaseTriglycerides
    Study

    n = 121

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    1.2 mg/day · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up.
    2 context sentences
    Summary · context
    One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included.
    Summary · context
    Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study.
  8. 08HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes and metabolic syndrome, carotid intima-media thickness fell during 18 months of liraglutide added to metformin.

    In plain wordsIn adults with type 2 diabetes and metabolic syndrome, the thickness of the carotid artery wall fell over 18 months of liraglutide added to metformin.

    Peptide
    Liraglutide
    Outcome
    DecreaseCarotid intima-media thickness
    Study

    n = 121

    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    1.2 mg/day · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up.
    2 context sentences
    Summary · context
    One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included.
    Summary · context
    Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study.
  9. 09HumanNon-randomized trialMechanism

    In adults with type 2 diabetes and metabolic syndrome treated with liraglutide, changes in cIMT were significantly associated with changes in triglycerides.

    In plain wordsIn adults with type 2 diabetes and metabolic syndrome on liraglutide, artery wall thickness changes were linked to triglyceride changes.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation of change in cIMT with change in triglycerides
    Study

    n = 121

    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    1.2 mg/day · 18 monthsAs given in this study (human).

    Measurements

    Correlation r
    0.362 r
    cIMT vs triglycerides

    Source sentences

    Summary
    Correlation analysis showed a significant association between changes in cIMT and triglycerides (r = 0.362; p < 0.0001).
    2 context sentences
    Summary · context
    One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included.
    Summary · context
    Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study.
  10. 10HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes and metabolic syndrome, the prevalence of metabolic syndrome fell during liraglutide treatment, and 26% no longer met the criteria after 18 months.

    In plain wordsIn adults with type 2 diabetes and metabolic syndrome on liraglutide added to metformin, 26% no longer met the criteria after 18 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseMetabolic syndrome prevalence
    Study

    n = 121

    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    1.2 mg/day · 18 monthsAs given in this study (human).

    Measurements

    No longer meeting MetS criteria
    26%
    18 months

    Source sentences

    Summary
    The MetS prevalence significantly reduced during the study, and the 26% of subjects no longer fulfilled the criteria for the MetS after 18 months.
    2 context sentences
    Summary · context
    One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included.
    Summary · context
    Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT01715428

Liraglutide and Cardio-Metabolic Risk Markers

University of Palermon = 300Jun 2012 to Dec 2015

Type-2 Diabetes

Trial pageClinicalTrials.govUpdated 22 Nov 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.